BIO Bio-Rad Laboratories Inc - Class A

  1. Stocks
  2. Healthcare
  3. NYSE: BIO

Price (delayed)

$327.11

Market cap

$8.75B

P/E Ratio

56.11

Dividend/share

N/A

EPS

$5.83

Enterprise value

$9.62B

?
Relative Growth: Rel. Growth: 26
Relative Strength: Rel. Strength: 65
Relative Valuation: Rel. Valuation: 45
Relative Profitability: Rel. Profitability: 54

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B) is a leader in developing, manufacturing, and marketing a broad range of products for the life science research and clinical diagnostics markets. Based ...

Highlights
The EPS has soared by 108% YoY but it has plunged by 79% from the previous quarter
The net income has soared by 108% YoY but it has shrunk by 78% QoQ
The company's quick ratio fell by 47% YoY and by 44% QoQ
The company's gross margin fell by 3% YoY
Sector: Healthcare
Industry: Medical Devices
Website: http://www.bio-rad.com
Peers: TMO BDX HBIO A

Key stats

What are the main financial stats of BIO

BIO stock price

How has the Bio-Rad Laboratories Inc - Class A stock price performed over time
Intraday
0.5%
1 week
3.38%
1 month
10.19%
1 year
14.94%
YTD
7.96%
QTD
11.41%

Financial performance

How have Bio-Rad Laboratories Inc - Class A's revenue and profit performed over time
Revenue
$2.59B
Gross profit
$1.34B
Operating income
$57.6M
Net income
$168.8M
Gross margin
51.9%
Net margin
6.5%
The net margin has surged by 108% year-on-year but it has dropped by 78% since the previous quarter
The net income has soared by 108% YoY but it has shrunk by 78% QoQ
BIO's operating margin has dropped by 78% year-on-year but it is up by 22% since the previous quarter
BIO's operating income has dropped by 77% year-on-year but it is up by 22% since the previous quarter

Price vs fundamentals

How does BIO's price correlate with its fundamentals

Growth

What is Bio-Rad Laboratories Inc - Class A's growth rate over time

Valuation

What is Bio-Rad Laboratories Inc - Class A stock price valuation
BIO P/E details
P/E
56.11
P/B
1.29
P/S
3.4
EV/EBIT
35.44
EV/EBITDA
35.44
EV/Sales
3.72
The EPS has soared by 108% YoY but it has plunged by 79% from the previous quarter
BIO's P/B is 16% above its last 4 quarters average of 1.1
The equity has contracted by 8% from the previous quarter but it has grown by 2.6% YoY
The stock's price to sales (P/S) is 19% less than its 5-year quarterly average of 4.2 but 17% more than its last 4 quarters average of 2.9

Efficiency

How efficient is Bio-Rad Laboratories Inc - Class A business performance
The ROS has soared by 110% YoY but it has plunged by 74% from the previous quarter
The company's return on invested capital has surged by 110% YoY but it has shrunk by 73% QoQ
The ROE has soared by 108% year-on-year but it has dropped by 78% since the previous quarter
Bio-Rad Laboratories Inc - Class A's ROA has soared by 108% YoY but it has plunged by 78% from the previous quarter

Dividends

What is BIO's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for BIO.

Financial health

How did Bio-Rad Laboratories Inc - Class A financials performed over time
The company's quick ratio fell by 47% YoY and by 44% QoQ
The company's current ratio fell by 46% YoY and by 43% QoQ
The debt is 80% smaller than the equity
The equity has contracted by 8% from the previous quarter but it has grown by 2.6% YoY
Bio-Rad Laboratories Inc - Class A's debt to equity has increased by 5% from the previous quarter but it has decreased by 4.8% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.